Important note: Information in this article was accurate in July 2006. The state of the art may have changed since the publication date.
Updated US perinatal guidelines
HIV Treat Bull - Vol. 7, No. 7/8, July/August 2006
The Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States has been revised to include an update of the “Antiretroviral Drug Resistance and Resistance Testing in Pregnancy” section to reflect new recommendations for resistance testing for HIV-infected pregnant women.
The Perinatal Working Group now recommends resistance testing for 1) all pregnant women not currently receiving antiretrovirals, before starting treatment or Mother To Child Transmission (MTCT) prophylaxis, and 2) all pregnant women receiving antenatal antiretroviral therapy who have virologic failure or who have sub-optimal viral suppression after initiation of antiretroviral therapy.
The Working Group also counsels against adding single-dose maternal/infant NVP to an ongoing highly active antiretroviral regimen, as this does not provide additional efficacy in reducing perinatal transmission and may result in NVP drug resistance in the mother.
Information in Table 6 from the November 17, 2005 document has been updated and replaced with a recommendation box at the beginning of the “Antiretroviral Drug Resistance and Resistance Testing in Pregnancy” section; the old Table 6 has been removed and the remaining tables have been renumbered accordingly.
The updated section and new references are highlighted in the document.
Updated slide sets to accompany the revised guidelines are also available
Excellent website with supporting documents and links to guidelines
2008-03-10
IB060707-26
©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.